Loading...
XSHG
600161
Market cap5.54bUSD
Jun 06, Last price  
20.15CNY
1D
4.73%
1Q
1.66%
Jan 2017
-13.56%
Name

Beijing Tiantan Biological Products Corp Ltd

Chart & Performance

D1W1MN
No data to show
P/E
25.72
P/S
6.61
EPS
0.78
Div Yield, %
0.74%
Shrs. gr., 5y
5.70%
Rev. gr., 5y
12.94%
Revenues
6.03b
+16.44%
343,358,631413,781,166530,504,687682,700,4311,100,252,9751,202,261,4091,394,395,3411,502,351,1601,836,504,0831,826,551,1271,617,985,9812,095,734,3011,765,169,6792,931,058,7283,281,859,5603,445,594,8654,112,155,6214,261,304,6225,180,441,7996,031,865,460
Net income
1.55b
+39.58%
68,999,532101,045,654104,702,668133,381,727211,659,754174,924,348233,349,955304,911,661372,028,783128,391,6739,977,207261,777,4411,179,942,696509,479,066894,253,782943,076,5911,068,813,8181,204,834,6911,109,888,5971,549,164,832
CFO
820m
-65.75%
131,685,718154,361,978153,548,280276,390,256448,226,847184,854,393353,150,675432,004,890566,433,984477,952,523473,258,905428,374,721218,389,433677,916,885642,468,858702,109,603980,350,1951,126,002,1902,393,576,031819,780,705
Dividend
Jun 20, 20240.15 CNY/sh
Earnings
Aug 26, 2025

Profile

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.
URL
https://www.tiantanbio.com/
IPO date
Jun 16, 1998
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,031,865
16.44%
5,180,442
21.57%
4,261,305
3.63%
Cost of revenue
3,272,693
3,159,525
2,643,916
Unusual Expense (Income)
NOPBT
2,759,172
2,020,916
1,617,389
NOPBT Margin
45.74%
39.01%
37.96%
Operating Taxes
434,953
289,140
221,438
Tax Rate
15.76%
14.31%
13.69%
NOPAT
2,324,219
1,731,777
1,395,951
Net income
1,549,165
39.58%
1,109,889
-7.88%
1,204,835
12.73%
Dividends
(82,390)
(137,317)
Dividend yield
0.13%
0.35%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
123,806
Long-term debt
89,711
48,830
304,983
Deferred revenue
107,442
101,904
Other long-term liabilities
1,240
100,801
4,105
Net debt
(2,595,945)
(4,652,184)
(3,501,984)
Cash flow
Cash from operating activities
819,781
2,393,576
1,126,002
CAPEX
(1,077,540)
Cash from investing activities
(1,280,657)
Cash from financing activities
(508,084)
FCF
(861,136)
1,509,879
(21,254)
Balance
Cash
2,685,656
4,554,949
3,712,890
Long term investments
1
146,065
217,883
Excess cash
2,384,063
4,441,992
3,717,707
Stockholders' equity
11,782,380
9,700,077
8,660,560
Invested Capital
12,302,673
8,437,594
8,010,385
ROIC
22.41%
21.06%
19.39%
ROCE
18.71%
15.66%
13.74%
EV
Common stock shares outstanding
1,986,109
1,977,372
1,647,810
Price
20.50
-33.74%
30.94
30.38%
23.73
-18.06%
Market cap
40,715,230
-33.45%
61,179,875
56.46%
39,102,520
-15.63%
EV
41,513,779
59,459,482
38,161,135
EBITDA
3,090,693
2,288,941
1,797,136
EV/EBITDA
13.43
25.98
21.23
Interest
5,121
6,001
2,411
Interest/NOPBT
0.19%
0.30%
0.15%